VORANIGO (vorasidenib citrate)
ANTINEOPLASTIC - ISOCITRATE DEHYDROGENASE-2 INHIBITOR (IDH2)·DIFFUSE ASTROCYTOMA·+1
SERVIER PHARMAC
Indication
Diffuse astrocytoma
Diffuse astrocytoma is an infiltrative, slow-growing primary central nervous system neoplasm arising from star-shaped glial cells known as astrocytes. Read more about Diffuse astrocytoma
1 drugs 1 manufacturers
Drugs that treat it
Common Diffuse astrocytoma therapies.
Filter & compare in the drug finder →Opens the drug finder with Diffuse astrocytoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonDiffuse astrocytoma is an infiltrative, slow-growing primary central nervous system neoplasm arising from star-shaped glial cells known as astrocytes.
Most commonly diagnosed in young to middle-aged adults, it typically develops in the cerebral hemispheres of the brain but can affect other neuroaxial sites.
Pathophysiologically, it is historically classified as a low-grade (World Health Organization grade 2) glioma characterized by cellular atypia and ill-defined margins that invade adjacent neural parenchyma without significant necrosis or microvascular proliferation.
Patients frequently present with new-onset seizures, persistent headaches, or progressive focal neurological deficits, and the neoplasm carries an inherent tendency over time to recur or progress to higher-grade malignancies.
- oncodaily.com
Diffuse astrocytoma is an infiltrative, slow-growing primary central nervous system neoplasm arising from star-shaped glial cells known as astrocytes Pathophysiologically, it is historically classified as a low-grade (World Health Organization grade 2) glioma characterized by cellular atypia and ill-defined margins that invade adjacent neural parenchyma without significant necrosis or microvascular proliferation
- mayoclinic.org
Diffuse astrocytoma is an infiltrative, slow-growing primary central nervous system neoplasm arising from star-shaped glial cells known as astrocytes
- mhsystem.org
Diffuse astrocytoma is an infiltrative, slow-growing primary central nervous system neoplasm arising from star-shaped glial cells known as astrocytes
- nih.gov
Most commonly diagnosed in young to middle-aged adults, it typically develops in the cerebral hemispheres of the brain but can affect other neuroaxial sites Pathophysiologically, it is historically classified as a low-grade (World Health Organization grade 2) glioma characterized by cellular atypia and ill-defined margins that invade adjacent neural parenchyma without significant necrosis or microvascular proliferation
- nih.gov
Most commonly diagnosed in young to middle-aged adults, it typically develops in the cerebral hemispheres of the brain but can affect other neuroaxial sites Patients frequently present with new-onset seizures, persistent headaches, or progressive focal neurological deficits, and the neoplasm carries an inherent tendency over time to recur or progress to higher-grade malignancies
- nih.gov
Most commonly diagnosed in young to middle-aged adults, it typically develops in the cerebral hemispheres of the brain but can affect other neuroaxial sites Patients frequently present with new-onset seizures, persistent headaches, or progressive focal neurological deficits, and the neoplasm carries an inherent tendency over time to recur or progress to higher-grade malignancies
- nih.gov
Pathophysiologically, it is historically classified as a low-grade (World Health Organization grade 2) glioma characterized by cellular atypia and ill-defined margins that invade adjacent neural parenchyma without significant necrosis or microvascular proliferation
- aurorahealthcare.org
Patients frequently present with new-onset seizures, persistent headaches, or progressive focal neurological deficits, and the neoplasm carries an inherent tendency over time to recur or progress to higher-grade malignancies
Personalize your experience
Follow Diffuse astrocytoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.